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Ming-Wei Lin1, Mei-Feng Huang2,3 and Meng-Hsing Wu2,3*Abstract
Objective: Polycystic ovary syndrome (PCOS) is a common endocrinologic disease in women. In the present study,
we examined the relationship of the IRS-1 Gly972Arg and IRS-2 Gly1057Asp polymorphisms to PCOS and phenotypic
features of PCOS in a Chinese population from Taiwan.
Materials and methods: A total of three hundred and forty genetically unrelated women with age from 18 to 45 years,
including two hundred and forty-eight PCOS patients and ninety-two control subjects, were recruited. The hormone and
biochemical measurements were evaluated for each woman. Genotyping of the IRS-1 gene Gly972Arg variant and IRS-2
gene Gly1057Asp variant were performed by using direct sequencing.
Results: We found significant difference in the genotypic distribution of IRS-2 gene Gly1057Asp between the PCOS group
and the control group (p = 0.004). The carriers of homozygous IRS-2 Asp had an increased risk of PCOS compared with
the carriers of Gly/Gly (OR 4.08, 95% C.I. 1.60-10.41, p = 0.003). No significant difference in genotype frequencies of IRS-1
Gly972Arg was observed between two groups. We further investigated the effect of interaction of IRS-1 Gly972Arg and
IRS-2 Gly1057Asp on the risk of PCOS and found that women carried IRS-1 Gly/Arg or IRS-2 Asp/Asp or carried both IRS-1
Gly/Arg and IRS-2 Asp/Asp had a much higher risk of PCOS compared with their counterpart, respectively (OR 2.49, 95%
C.I. 1.16-5.37, p = 0.019; OR 11.87, 95% C.I. 1.21-116.84, p = 0.034). We further found, the non-obese PCOS patients carried
significantly higher frequency of IRS-2 Asp/Asp as compared with the control group (p = 0.004). A significant effect
of interaction of carrying both IRS-1 Gly/Arg and IRS-2 Asp/Asp was also observed in the non-obese PCOS patients
(p = 0.003), but not in the obese PCOS patients.
Conclusions: In this study, we found significant association of the variant of IRS-2 gene as well as the interaction
of IRS-1 and IRS-2 genes with PCOS, especially in non-obese women. Women with IRS-2 homozygous Asp variant
may be considered as a risk factor for PCOS that needs early detection to prevent further complication in the
Chinese population from Taiwan.
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Polycystic ovary syndrome (PCOS) is a highly prevalent
syndrome of ovarian dysfunction affecting approximately
5-10% of reproductive-aged women [1]. The PCOS is char-
acterized by chronic anovulation, hyperandrogenism, and/
or the presence of polycystic ovary morphology. The
syndrome demonstrates a significant reproductive and
metabolic impact, and is associated with increased risk
of type 2 diabetes, dyslipidemia, cardiovascular disease,
endometrial carcinoma, and also leads to infertility
[2-6]. In general, PCOS can be viewed as a heteroge-
neous androgen excess disorder with various degrees of
gonadotropic and metabolic abnormalities determined
by the interaction of multiple genetic and environmen-
tal factors. Insulin resistance, particularly in skeletal
muscle and adipose tissue with sensitivity in ovarian
tissue, affects up to 70% of women with PCOS and is a
risk factor in PCOS women for developing type 2 diabetes
[7,8]; however, the mechanisms for defects in insulin sig-
naling in the disorder are complex [9] and have not been
fully elucidated.
The insulin receptor is a heterotetramer consist of two
α, β-dimers. The α-subunit contains the ligand-binding
site, while the β-subunit contains a ligand-activated tyro-
sine kinase. Once tyrosine is phosphorylated, the insulin
receptor phosphorylates two intracellular substrates, in-
sulin receptor substrate-1 (IRS-1) and insulin receptor
substrate-2 (IRS-2). The IRS-1 serves as a docking mol-
ecule for signaling and will activate the enzyme phos-
phatidylinositol 3-kinase (PI3K), a necessary step for the
initiation of several effects of insulin such as glucose
transport. When the IRS-1 is dysfunctional, the IRS-2 is
the main docking protein for the intracellular propa-
gation of the insulin signal [10]. However, the IRS-2
requires a higher insulin concentration for activation,
the hallmark of insulin resistance.
The IRS-1 gene is located on chromosome 2q36 and
encodes a 1,242-amino acid protein with a molecular
weight of 131.6 kDa. The most common variant,
Gly972Arg (rs1801278), was reported to be associated
with insulin resistance, type 2 diabetes and PCOS
[11-14]. The IRS-2 gene is located on chromosome
13q34 and encodes a protein of 1,354 amino acids.
Moreover, the most common variant Gly1057Asp
(rs1805097) in the IRS-2 gene has also been reported
to influence the susceptibility to insulin resistance and
type 2 diabetes in PCOS women [15-17]. Two recent
meta-analysis of PCOS studies reported that the IRS-1
Gly972Arg polymorphism concerning the Gly/Arg vs.
Gly/Gly genotype is significantly associated with the
risk of developing PCOS and that this association is
primarily mediated by increasing the levels of fasting
insulin [18,19]. However, another meta-analysis of five
studies with 519 cases and 883 controls failed todemonstrate significant association between IRS-2
Gly1057Asp polymorphism and PCOS [19].
Although the meta-analysis reported positive associa-
tions of the IRS-1 Gly972Arg with PCOS and no associ-
ation between the IRS-2 Gly1057Asp polymorphism
and PCOS, the results from different studies were con-
troversial and were lack of data from Chinese ethnic
origin. The aim of the study was to investigate if IRS-1
Gly972Arg and IRS-2 Gly1057Asp influence insulin re-
sistance and are associated with risk of PCOS in the
Chinese PCOS patients and controls from Taiwan.Materials and methods
Subjects
A total of three hundred and forty genetically unrelated
women with age from 18 to 45 years, including two hun-
dred and forty-eight PCOS patients and ninety-two con-
trol subjects, were recruited from the Obstetrics and
Gynecology clinics of the National Cheng Kung University
Hospital (Tainan, Taiwan). This study was approved by the
Institution Review Board of the hospital. Written in-
formed consent was obtained from all participants. The
study was in compliance with the Helsinki Declaration.
All the participants are Han Chinese from the same geo-
graphical region in Taiwan.
The diagnosis of PCOS was assigned according to the
2003 Rotterdam criteria (The Rotterdam ESHRE/ASRM-
sponsored PCOS consensus workshop group, 2004). The
criteria are as follows: (i) oligo- and/or anovulation that
is defined as the absence of menstruation for more than
35 days; (ii) clinical and/or biochemical signs of hyper-
androgenism: the former is defined as and modified
Ferriman-Gallwey score of 6 or greater with/without
acne or androgenic alopecia, and the latter as total tes-
tosterone level of more than 0.95 ng/ml; and (iii) poly-
cystic ovarian morphology identified by ultrasound scan.
Women fulfilled any two of above three criteria were
diagnosed as PCOS. The exclusion criteria included
non-classic congenital adrenal hyperplasia, hyperpro-
lactinemia, and androgen-secreting tumors. All the pa-
tients did not take any medication having effect on insulin
levels or hormonal medications, including contraceptive
pills, at least two months before their participating in the
study. The control patients were enrolled from infertility
clinic prior to entering an in vitro fertilization program
due to tubal and/or male factors with free of menstrual
cycle irregularities, clinical or biochemical hyperandrogen-
ism, polycystic ovaries on ultrasound examination, or
history of systemic/endocrine disease.Hormone and biochemical measurement
The blood samples were obtained in the early follicular
phase of menstrual cycle, but the random blood samples
Table 1 Descriptive characteristics of the study
participants
PCOS group Control group Pa
Subjects (n) 248 92
Age (years) 28.2 ± 5.4 32.4 ± 5.5 < 0.001
Body weight (kg) 62.7 ± 14.8 56.9 ± 10.3 < 0.001
Body height (cm) 159.4 ± 5.3 159.7 ± 5.3 0.681
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consisted of complete hormonal, including serum follicle
stimulating hormone (FSH) luteinizing hormone (LH),
thyroid-stimulating hormone (TSH), prolactin (PRL),
estradiol (E2), 17-OH-progesterone (17-OHP), total tes-
tosterone, and sex-hormone binding globulin (SHBG),
and metabolic evaluation, including evaluation of lipid,
glucose and insulin levels. All subjects received a 75-g
glucose monohydrate in 350-ml water after a 10-h over-
night fasting. A total of 5 ml blood sample was drawn
before glucose loading and another 5 ml blood samples
was drawn at 120 minutes after the glucose loading.
Plasma glucose and insulin concentrations were deter-
mined by a glucose oxidase method in a glucose analyzer
(model 2300, YSI, Yellow Springs, OH, USA) and by an
automated chemiluminescence system (ADVIA Centaur
Immunoassay System, Siemens Healthcare Diagnostics,
Deerfield, IL, USA), respectively. Insulin resistance was
evaluated using the homeostasis model analysis (HOMA)
[fasting glucose (mg/dL) × fasting insulin (μU/mL)/405],
quantitative insulin-sensitivity check index (QUICKI)
[1/[log(fasting insulin) + log(fasting glucose)], and the
fasting glucose-to-insulin ratio (A/I).BMI (kg/m2) 24.7 ± 5.5 22.3 ± 4.0 < 0.001
Waist circumference (cm) 83.9 ± 13.5 82.7 ± 12.2 0.705
Systolic BP (mmHg) 117 ± 15 115 ± 14 0.178
Diastolic BP (mmHg) 70 ± 11 70 ± 11 0.852
Total cholesterol (mg/dL) 181.9 ± 43.0 189.9 ± 35.5 0.285
Triglycerides (mg/dL) 104.3 ± 67.5 91.6 ± 46.0 0.258
HDL-C (mg/dL) 53.8 ± 12.8 58.6 ± 17.4 0.063
LDL-C (mg/dL) 114.4 ± 43.8 115.3 ± 32.2 0.914
Fasting insulin 9.9 ± 10.5 9.3 ± 15.5 0.733
2 hr insulin 54.8 ± 52.0 32.5 ± 26.5 < 0.001
HbA1C (%) 5.5 ± 0.5 5.3 ± 0.3 0.037
AC (mg/dL) 89.4 ± 12.0 87.6 ± 5.3 0.086
PC (mg/dL) 110.4 ± 36.2 99.0 ± 25.9 0.036
HOMA index (mg/L) 2.3 ± 2.6 2.0 ± 3.4 0.542
A/I (AC/ Fasting Insulin) 16.7 ± 11.7 17.9 ± 11.4 0.489
QUICKI index (mg/L) 3.4 ± 0.8 3.5 ± 0.7 0.674
SHBG (nmol/L) 37.8 ± 29.7 59.6 ± 53.8 0.007
17-OHP (ng/mL) 1.8 ± 1.4 2.0 ± 1.3 0.529
Hirsutism score 5.6 ± 3.8 3.2 ± 2.9 0.016
TSH (μU/mL) 2.1 ± 1.3 2 .0 ± 1.0 0.618
LH (mIU/mL) 8.0 ± 5.3 4.3 ± 2.5 < 0.001
FSH (mIU/mL) 5.6 ± 2.0 6.0 ± 2.4 0.212
E2 (pg/mL) 45.8 ± 22.9 43.1 ± 27.5 0.484
Testosterone (ng/mL) 0.55 ± 0.31 0.35 ± 0.19 < 0.001
Free androgen index 5.98 ± 4.61 4.04 ± 4.02 0.043
PRL (ng/mL) 12.5 ± 6.4 13.5 ± 6.3 0.248
aCompared by t test.Genotyping by re-sequencing
A total of 10 mL whole blood sample was taken from
each subject for genotyping. Genomic deoxyribonucleic
acid (DNA) was extracted from whole blood using the
GeneMark extraction Kit (GeneMark Technology Co.,
Ltd., Tainan, Taiwan, ROC) according to the manufac-
turer’s instruction. Genotypings of the IRS-1 gene
Gly972Arg variant (rs 1801278) and the IRS-2 gene
Gly1057Asp (rs1805097) variant were performed by
using direct sequencing. The primer sequences for the
IRS-1 Gly972Arg polymorphism were 5’-GGGTCGAG
ATGGGCAGACT-3’ and 5’-GGGACAACTCATCTGC
ATGGT-3’; while for the IRS-2 Gly1057Asp polymorph-
ism were 5’-GGAGCTGTACCGCCTGCC-3’ and 5’-AC
CAAAAGCCATCTCGGTGT-3’, respectively. Twenty to
fifty nanograms of total genomic DNA was amplified in
a total volume of twenty-five microliter containing 900
nM primers, and 12.5 ul of Taq-Man universal PCR
master mix (Perkin-Elmer, Applied Biosystems Division)
by using the standard polymerase chain reaction (PCR)
techniques. The PCR amplification was performed with
the following conditions: 95°C, 10 min; followed by
40 cycles of 95°C 1 min, 53°C 30 secs., and 72°C 30 secs.
The final step was 72°C for 10 minutes. The PCR reac-
tions were performed in 96-well microtiter plates and
the sequencing reactions were performed using the ABI
BigDye Terminator reagents (Applied Biosystems, Foster
City, CA). The PCR products were sent to the Nucleic
Acid Sequencing Center of National Cheng-Kung Universityfor sequencing by using the ABI 3100 DNA sequencer
(Applied Biosystems, Foster City, CA). The sequence
data were analyzed by using the PolyPhred software
(v5.04) [20]. The genotypes were assigned to the sub-
jects independently by two individuals blinded to the
subject information.Statistical analysis
Data were expressed as mean ± SD or number (%). Two-
sample t test was applied to compare the mean differences
between groups. Differences in genotypic frequencies and
categorical data between groups were compared by using
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at each SNP was tested using Pearson’s chi-squared
tests. Logistic regression analyses were performed to
examine the differences in genotypic frequencies and
interaction of two SNPs between the PCOS and con-
trol groups. Odds ratios and 95% confidence interval
(ORs ± 95% CI) from the logistic regression model
after controlling for other covariates were used to esti-
mate the magnitude of the association between geno-
type and PCOS. The statistical analyses were performed
using the SPSS program (Version 17.0, SPSS Inc., Chicago,
IL, USA). A p value less than 0.05 was considered as statis-
tically significant.Results
Clinical and biochemical characteristics of the study
population
The clinical and biochemical characteristics of the PCOS
and control groups were summarized in Table 1. The
PCOS subjects were significant younger and had higher
body weight and body mass index as compared with the
control subjects. As we could expect, the levels of LH,
testosterone, free androgen index, SHBG and Hirsutism
score were significantly higher in the PCOS group than
in the control group. Moreover, the PCOS patients also
had significantly elevated levels of glucose, insulin at
2 hour during the oral glucose tolerance test, and HbA1C
(glucose: 110.4 ± 36.2 mg/dL; insulin: 54.8 ± 52.0 mg/dL;
HbA1C: 5.5 ± 0.5 (%) ) compared with the control subjects
(glucose: 99.0 ± 25.9 mg/dL; insulin: 32.5 ± 26.5 mg/dL;
HbA1C: 5.3 ± 0.3 (%)). The results remained significantTable 2 Genotypic distribution of polymorphisms in the IRS
group
PCOS group Control group
IRS-1 Gly972Arg (n = 248) (n = 92)
GG 220 (88.7%) 84 (91.3%)
GA 28 (11.3%) 8 (8.7%)
IRS-2 Gly1057Asp (n = 95) (n = 74)
GG 12 (12.6%) 25 (33.8%)
GA 18 (18.9%) 13 (17.6%)
AA 65 (68.4%) 36 (48.6%)
GG + GA 30 (31.6%) 38 (51.4%)
AA 65 (68.4%) 36 (48.6%)
IRS-1 and IRS-2 (n = 95) (n = 74)
GG/GG + GA 26 (27.4%) 35 (47.3%)
GA/AA 58 (61.1%) 38 (51.4%)
GA and AA 11 (11.6%) 1 (1.4%)
aCompared by chi-square test.
bCompared by logistic regression after adjusting for age and BMI.after adjusting the age effect between the PCOS and
control groups.IRS-1 and IRS-2 genotypes and gene-gene interaction
There was significant difference in IRS-2 gene Gly1057Asp
genotypic distribution between the PCOS group and the
control group (chi-squared test p = 0.004). The carriers of
homozygous IRS-2 Asp had an increased risk of PCOS
compared with the carriers of Gly/Gly after adjusting for
age and BMI (OR =4.08, 95% C.I. 1.60-10.41, p = 0.003)
(Table 2). However, no significant difference in genotype
frequencies of IRS-1 Gly972Arg was observed between
two groups (Table 2). The IRS-1 Gly972Arg variant was in
Hardy-Weinberg equilibrium, but the IRS-2 Gly1057Asp
variant was not in Hardy-Weinberg equilibrium in both
PCOS and control groups.
When we further investigated the effect of inter-
action of IRS-1 Gly972Arg and IRS-2 Gly1057Asp on
the risk of PCOS, we found that women carried IRS-1
Gly/Arg or IRS-2 Asp/Asp had an increased risk of
PCOS (OR = 2.49, 95% C.I. 1.16-5.37, p = 0.019).
Moreover, carriers of both IRS-1 Gly/Arg and IRS-2
Asp/Asp had a much higher risk of PCOS compared
with their counterpart (OR = 11.87, 95% C.I. 1.21-116.84,
p = 0.034) (Table 2).IRS-2 genotype and clinical phenotypes
We then evaluated the association between IRS-2
Gly1057Asp genotype and clinical phenotypes in all
subjects of both PCOS (n = 95) and control (n = 74)
groups and found the levels of fasting insulin, and1 and IRS2 genes between the PCOS group and control









0.003 2.49 (1.16-5.37) 0.019
11.87 (1.21-116.84) 0.034
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rying the homozygous Asp/Asp genotype than their
counterparts (Gly/Gly and Gly/Asp) (Table 3). How-
ever, when we focused on the PCOS group, the associ-
ation between IRS-2 genotype and clinical phenotypes
became statistically insignificant (data not shown).IRS-1 and IRS-2 genotypes and obesity
When the study subjects were classified into obese (obese:
BMI ≥ 27 kg/m2) (PCOS n = 72; Control n = 9) and non-
obese groups (BMI < 27 kg/m2) (PCOS n = 176; Control
n = 83), the non-obese PCOS patients carried significantlyTable 3 Relationship between clinical phenotypes and
genotypes of the IRS-2 Gly1057Asp polymorphism
GG + GA AA pa
Subjects (n) 68 101
Age (years) 30.0 ± 6.2 29.7 ± 6.0 0.688
Body weight (kg) 58.7 ± 13.4 61.3 ± 13.3 0.208
Body height (cm) 159.8 ± 5.3 160.1 ± 5.6 0.779
BMI (kg/m2) 23.0 ± 5.0 23.9 ± 4.8 0.219
Waist circumference (cm) 80.8 ± 12.1 86.2 ± 11.6 0.058
Systolic BP (mmHg) 113 ± 12 117 ± 15 0.055
Diastolic BP (mmHg) 69 ± 10 71 ± 11 0.209
Total cholesterol (mg/dL) 181.7 ± 48.3 180.6 ± 45.5 0.908
Triglycerides (mg/dL) 91.3 ± 59.5 110.8 ± 68.3 0.152
HDL-C (mg/dL) 55.6 ± 12.0 54.3 ± 13.6 0.653
LDL-C (mg/dL) 111.2 ± 33.4 114.7 ± 28.3 0.598
Fasting insulin 6.7 ± 6.1 11.0 ± 15.3 0.025
2 hr insulin 38.3 ± 31.6 54.2 ± 56.7 0.087
HbA1C (%) 5.4 ± 0.3 5.5 ± 0.5 0.544
AC (mg/dL) 87.6 ± 5.8 90.4 ± 16.8 0.164
PC (mg/dL) 105.4 ± 29.9 109.3 ± 40.2 0.557
HOMA index (mg/L) 1.5 ± 1.6 2.6 ± 3.8 0.022
A/I (AC/ Fasting Insulin) 19.1 ± 11.3 17.4 ± 12.3 0.427
QUICKI index (mg/L) 3.6 ± 0.8 3.5 ± 0.8 0.454
SHBG (nmol/L) 48.5 ± 41.9 40.2 ± 42.5 0.337
17-OHP (ng/mL) 1.8 ± 1.3 2.0 ± 1.4 0.400
Hirsutism score 4.6 ± 3.3 5.8 ± 3.9 0.289
TSH (μU/mL) 2.4 ± 1.5 2.0 ± 0.9 0.044
LH (mIU/mL) 6.8 ± 4.5 7.6 ± 5.5 0.367
FSH (mIU/mL) 5.6 ± 2.3 6.0 ± 2.3 0.445
E2 (pg/mL) 42.5 ± 23.4 48.2 ± 25.5 0.217
Testosterone (ng/mL) 0.4 ± 0.3 0.5 ± 0.3 0.289
Free androgen index 4.60 ± 3.61 6.01 ± 4.61 0.217
PRL (ng/mL) 12.8 ± 6.5 12.3 ± 6.1 0.692
aCompared by t test.higher frequency of IRS-2 Asp/Asp as compared with
the control group (p = 0.004) (Table 4). A significant ef-
fect of interaction of carrying both IRS-1 Gly/Arg and
IRS-2 Asp/Asp was also observed in the non-obese
PCOS patients (p = 0.003), but not in the obese PCOS
patients (p = 0.834).
Discussion
PCOS is a highly prevalent syndrome of ovarian dys-
function and affects up to 10% of reproductive age
women, nearly half of whom will develop impaired glu-
cose tolerance or type 2 diabetes [8]. This predisposition
to type 2 diabetes is a consequence of defects in both in-
sulin action [9] and insulin secretion [15]. Recently, several
polymorphisms in IRS-1 and IRS-2 have been implicated in
PCOS [16,21]. However, the results in PCOS patients were
in considerable disagreement and, therefore, the role of
these variants in the pathogenesis of insulin resistance and
PCOS remains debatable. In the present study, we found
significant association of the variants of IRS-2 gene as
well as the interaction of IRS-1 and IRS-2 genes with
PCOS, especially in non-obese women. We also found
significantly increased levels of fasting insulin, and el-
evated HOMA index in women carrying the homozy-
gous Asp/Asp genotype than their counterpart (Gly/Asp
and Gly/Gly).
In our study, we found women with homozygous IRS-2
Asp genotypes had a significantly increased risk of PCOS
compared with the carriers of homozygous IRS-2 Gly
(OR = 4.08, 95% CI: 1.60-10.41). We also observed women
with the IRS-2 Asp/Asp genotype had significantly higher
fasting insulin and HOMA index compared with those
with Gly/Asp and Gly/Gly genotypes. However, Ehrmann
et al. reported that the IRS-2 Gly/Gly genotype carriers of
their nondiabetic subjects had significantly higher 2-h oral
glucose tolerance test glucose levels compared with
those with Gly/Asp and Asp/Asp genotypes in whites
or Gly/Asp genotype in African-Americans [15]. The
susceptibility allele of IRS-2 Gly1057Asp reported in
our population is completely opposite from those re-
ported in other populations. When we further examined
the minor allele frequency of IRS-2 Gly1057Asp in differ-
ent populations, we observed that the Gly is the minor al-
lele in our population, while it is Asp in Caucasians and
African Americans [19]. The increased homozygous IRS-2
Asp polymorphism in the population from Taiwan might
be due to different evolutionary force, such as genetic
drift, or selection pressure. It may be also due to different
techniques used for genotyping of allelic variants. Our
study used PCR following by re-sequencing to conduct
our genotyping which will produce more reliable
genotypes.
We did not find significant difference in genotype fre-
quencies of IRS-1 Gly972Arg between the PCOS and
Table 4 Genotypic distribution of polymorphisms in the IRS1 and IRS2 genes between the control group and the PCO
group stratified by BMI
Non-obese group (BMI <27) Obese group (BMI ≥ 27)
PCOS group Control group pa PCOS group Control group Pb
(n = 176) (n = 83) (n = 72) (n = 9)
IRS-1 Gly972Arg
GG 156 (88.6%) 77 (92.8%) 0.792 64 (88.9%) 7 (77.8%) 0.307
GA 20 (11.4%) 6 (7.2%) 8 (11.1%) 2 (22.2%)
IRS-2 Gly1057Asp (n = 70) (n = 68) (n = 25) (n = 6)
GG 8 (11.4%) 24 (35.3%) 0.004 4 (16.0%) 1 (16.7%) 1.000
GA 15 (21.4%) 12 (17.6%) 3 (12.0%) 1 (16.7%)
AA 47 (67.1%) 32 (47.1%) 18 (72.0%) 4 (66.7%)
GG + GA 23 (32.9%) 36 (52.9%) 0.027 7 (28.0%) 2 (33.3%) 1,000
AA 47 (67.1%) 32 (47.1%) 18 (72.0%) 4 (66.7%)
IRS-1 and IRS-2 (n = 70) (n = 68) (n = 25) (n = 6)
GG / GG + GA 20 (28.6%) 33 (48.5%) 0.003 6 (24.0%) 2 (3.3%) 0.834
GA / AA 43 (61.4%) 35 (51.5%) 15 (60.0%) 3 (50.0%)
GA and AA 7 (10.0%) 0 (0.0%) 4 (16.0%) 1 (16.7%)
a,bComparison between the PCOS group and the control group by chi-square test.
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sults from meta-analysis [19]. This inconclusive results
in our population deserved further investigations with
larger independent sample in the Chinese population
from Taiwan.
We found the IRS-1 Gly972Arg variant was in Hardy-
Weinberg equilibrium, but the IRS-2 Gly1057Asp variant
was not in Hardy-Weinberg equilibrium in both PCOS
and control groups. The possible reasons why the IRS-1
SNP in the control group is in equilibrium while it is
not for the IRS-2 marker may be due to different selec-
tion pressure for IRS-1 and IRS-2 variants or the IRS-2
Gly1057Arg variant is a recent mutation.
Our study found significant association of the variants
of IRS-2 gene as well as the interaction of IRS-1 and
IRS-2 genes with PCOS. The magnitudes of associations
were more profound in non-obese women group
(Table 4). A couple of studies reported that the associ-
ation of the Asp1057 allele in IRS-2 with type 2 diabetes
may be mediated by interaction of the polymorphism
with obesity on several diabetes-related traits [20,22].
The exact molecular mechanism of IRS-2 Gly1057Asp
polymorphism on insulin action is not clear, but it is
speculated that this variant introduces an exchange of a
charged amino acid (Asp) with a neutral one (Gly) in the
domain of IRS-2 molecule located in between two puta-
tive tyrosine phosphorylation sites (at positions 1042 &
1072) of the protein. This could produce alterations in
downstream signaling through IRS-2 [22].
In this study, despite the PCOS subjects were signifi-
cant younger, with higher risk of morphologic change,glucose intolerance, and endocrine dysfunction than the
control subjects (Table 1), we only found increased levels
of fasting insulin, and elevated HOMA index in women
carrying the homozygous Asp/Asp genotype than their
counterpart (Gly/Gly and Gly/Asp) (Table 3). It may be
probable that women with IRS-2 homozygous Asp vari-
ant are more likely to show early signs of metabolic risks
rather than to be associated with the development of
PCOS.
In our previous study, the level of interleukin-6, which
is considered as an early low-grade chronic inflamma-
tory marker, was increased in PCOS women. But the ele-
vated interleukin-6 level was reduced significantly after
metformin treatment, especially among PCOS women
with IRS-2 homozygous Asp variant [23]. In this study,
we did not have the information of metformin treatment,
thus we are unable to evaluate the effect of metformin
treatment.
There are several limitations in the study. Firstly, our
control subjects were recruited from outpatient department
of the hospital, so they might not be well-presented as in
the general population. We were also aware that the inclu-
sion and exclusion criteria of control subjects we applied in
the study might result in over-estimation of the odds ratio
of the IRS-2 gene on PCOS [24]. The control subjects of
the study were enrolled from infertility clinic prior to en-
tering an in vitro fertilization program due to tubal and/or
male factors with free of menstrual cycle irregularities,
clinical or biochemical hyperandrogenism, polycystic ovar-
ies on ultrasound examination, or history of systemic/
endocrine disease. General speaking, they were normal in
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problem. Therefore, they could be viewed as normal in
male factor but mechanical reason in tubal factor. The
issue of over-estimation of odds ratio might not be as se-
vere as we suspect. Secondly, despite we found that the
levels of 2-hour insulin, glucose, and HbA1C in the PCOS
group significantly higher than the control group, how-
ever, we could not find significant differences in HOMA
index, A/I, and QUICK index between two groups. The
possible reason is that our PCOS group is significantly
younger than the control group. For younger PCOS
women, the insulin sensitivity/resistance may be normal
or only mild hyperinsulinemia. Thirdly, in the oral glucose
tolerance test, we only measured the glucose and insulin
levels at the fasting and 2-hour time points, thus may limit
us to capture the entire picture of insulin sensitivity/resist-
ance during the time course. Lastly, although significant
association of the variant of IRS-2 gene and its interaction
effect with IRS-1 gene related to PCOS was found, the
sample size of our study is relatively small. In order to
confirm our findings, further larger well-designed studies,
especially in different ethnic populations are warranted.
In summary, we found significant association of the
variants of IRS-2 gene as well as the interaction of IRS-1
and IRS-2 genes with PCOS, especially in non-obese
women. Women with IRS-2 homozygous Asp variant
may be considered as a risk factor for PCOS that needs
early detection to prevent further complications in the
Chinese population of Taiwan.Competing interests
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